JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M112068200 on February 26, 2002

J. Biol. Chem., Vol. 277, Issue 18, 15697-15702, May 3, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/18/15697    most recent
M112068200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, X.
Right arrow Articles by Oren, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, X.
Right arrow Articles by Oren, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

p53 Activation by Nitric Oxide Involves Down-regulation of Mdm2*

Xinjiang Wang, Dan Michael, Gilbert de MurciaDagger , and Moshe Oren§

From the Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel and Dagger  Unite 9003 du CNRS, Ecole Superieure de Biotechnologie de Strasbourg, 67400 Illkirch-Graffenstaden, France

Received for publication, December 18, 2001, and in revised form, February 13, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Nitric oxide (NO) is an important bioactive molecule involved in a variety of physiological and pathological processes. At the same time, NO is also an inducer of stress signaling, owing to its ability to damage proteins and DNA. NO was reported to be a potent activator of the p53 tumor suppressor protein. However, the mechanisms underlying p53 activation by NO remain to be elucidated. We report here that NO induces the accumulation of transcriptionally active p53 in a variety of cell types and that NO signaling to p53 does not require ataxia telangiectasia-mutated (ATM), poly(ADP-ribose) polymerase 1, or the ARF tumor suppressor protein. In mouse embryonic fibroblasts, NO elicits a down-regulation of Mdm2 protein levels that precedes the rise in p53. NO-induced down-regulation of Mdm2 protein but not its mRNA also occurs in several p53-deficient cell types and is thus p53-independent. The drop in endogenous Mdm2 levels following NO treatment is accompanied by a corresponding reduction in the rate of p53 ubiquitination. Thus, the down-regulation of Mdm2 by NO is likely to contribute to the activation of p53.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

p53 is one of the best studied tumor suppressors. It is now appreciated that p53 is a pivotal integrator of stress signaling, and that many diverse types of stress can evoke a p53 response (1, 2). p53 is typically a very short-lived protein under normal conditions because of its fast proteasomal degradation. A key feature of the p53 response is p53 stabilization, leading to a rapid increase in p53 steady-state levels. Abundant evidence indicates that p53 stabilization largely relies on post-translational events that uncouple p53 from its proteasomal degradation (3, 4). A major E31 ubiquitin ligase for p53, whose activity serves as a rate-limiting factor for p53 degradation, is Mdm2 (5-7). Interestingly, the expression of the mdm2 gene is regulated by p53 itself (8, 9). This p53-Mdm2 autoregulatory feedback loop has been a focus of research in recent years, leading to the realization that many stress signals impinge on this loop to modulate the physical and functional interplay between p53 and Mdm2.

Different types of stress engage different mechanisms to uncouple the p53-Mdm2 feedback loop (10). In the case of ionizing radiation, the ATM kinase is essential for the rapid accumulation of p53. Ionizing radiation gives rise to at least three ATM-dependent events that impact on the p53-Mdm2 feedback loop, i.e. the phosphorylation of p53 on Ser-15 and Mdm2 on Ser-395 by ATM itself (11-13), and on Ser-20 of p53 by ATM-activated CHK2, a human checkpoint kinase (14, 15). In the case of aberrant oncogene expression, oncogenes such as c-Myc, Ras, and beta -catenin induce the expression of ARF, which binds to Mdm2 and inhibits its E3 ubiquitin ligase activity (16-19). Moreover, the binding of ARF to Mdm2 can sequester Mdm2 in the nucleolus (20, 21). Both of these mechanisms are proposed to reduce p53 ubiquitination and thereby increase its stability.

Nitric oxide (NO) is an important bioactive molecule involved in a variety of physiological and pathological processes. This membrane permeable and extremely short-lived (biological half-life: 1-10 s) molecule has been shown to be a regulator of cell killing by macrophages, a mediator of vasodilation and a neurotransmitter. Virtually every type of mammalian cell is under the influence of NO (22), because it is widely and actively synthesized. NO can be formed either by specific nitric-oxide synthases, which metabolize arginine to citrulline with the formation of NO or by nonenzymatic mechanisms involving the reduction of nitrite to NO under acidic and highly reduced conditions (reviewed in Ref. 23). NO can be stored in the form of S-nitrosothiols. In fact, S-nitrosothiols formed upon the reaction of NO with redox-activated thiols represent an active storage pool for NO (reviewed in Ref. 24).

The ability of NO to induce p53 accumulation has been observed in several studies. p53 accumulation was shown to occur upon treatment with exogenous NO donors in primary normal human fibroblasts, the murine monocyte/macrophage cell line RAW 264.7, the human promyelocytic leukemia cell line U937, and the human glioblastoma cell line A172 (25-27). However, the molecular mechanisms underlying the induction of p53 by NO have not been elucidated. We now report that NO signaling to p53 is independent of ATM, poly(ADP-ribose) polymerase 1 (PARP-1), or ARF. Of note, the induction of p53 by NO is preceded by a decrease in Mdm2 protein levels. This down-regulation of Mdm2 may be one of the events that contribute to p53 activation by NO.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells and Tissue Culture-- Primary mouse embryonic fibroblasts (MEFs) were prepared from day 13.5 embryos and propagated at 37 °C in Dulbecco's modified Eagle's medium supplemented with nonessential amino acids, 60 µM beta -mercaptoethanol, and 10% heat-inactivated fetal bovine serum (FBS, Sigma). MEFs were typically used after four passages in culture. AG03057 (ATM +/-, wtp53, mother) and AG03058 (ATM-/-, wtp53, daughter) cells were obtained from the National Institute of General Medical Sciences Human Genetic Mutant Cell Repository (Coriell Institute, Camden, NJ). AG03057 and AG03058 and WI-38 cells (human fetal lung fibroblasts, wtp53) were maintained in minimum Eagle's medium supplemented with 20% non-heat-inactivated FBS. ARF knock-out MEFs were obtained from Dr. C. Sherr. p53-null mouse fibroblasts (line 35-8) were from Dr. G. Lozano. C3 cells (ATM +/- human lymphocytes immortalized by Epstein-Barr Virus) were obtained from Dr. Y. Shiloh. PARP knock-out 3T3 cells and ARF-null and p53-null mouse fibroblasts as well as U2-OS cells (human osteosarcoma, wtp53) were maintained at 37 °C in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated FBS. ML-1 (human leukemic cells, wtp53), H1299 cells (human lung adenocarcinoma, p53-null), and C3 cells were maintained at 37 °C in RPMI 1640 medium supplemented with 10% heat-inactivated FBS. HCT116 colorectal carcinoma cells in which the p53 gene has been eliminated by somatic knock-out (28) were provided by Dr. B. Vogelstein and maintained in McCoy's 5A medium supplemented with 10% FBS.

Chemicals-- s-Nitroso-n-acetylpenicillamine (SNAP) (Sigma) and S-nitroso-glutathione (GSNO) (Alexis Biochemicals) were dissolved in PBS-/- at a concentration of 50 mM and stored at -80 °C in small aliquots. C-PTIO (Biomol Research Laboratories, Inc.) was dissolved in PBS-/- at 10 mM, stored at -80 °C, and used at a final concentration of 10 µM. MG132 (Calbiochem) was dissolved in Me2SO at a concentration of 50 mM and used at a final concentration of 25 µM. Cycloheximide (Sigma) was dissolved in PBS-/- at 10 mg/ml and used at a final concentration of 10 µg/ml.

Retroviral Infection-- High titer retroviral stocks were produced by transfecting retroviral constructs pBabe-puro or pBabe-PARP into 293T cells (2 × 106/10-cm dish) by the calcium phosphate coprecipitation method together with the ecotropic packaging vector pSV-psi E-MLV, providing ecotropic packaging helper function. Virus-containing culture supernatants were collected 24-72 h post-transfection at 6-h intervals and pooled together. PARP knock-out 3T3 cells (2 × 105/10-cm dish) were infected with filtered supernatants. Fresh supernatants were added three times at 4-h intervals. 48 h post-infection, cells were trypsinized and replated for experiments.

Transfections-- HCT116 cells were plated at 0.5 × 106/6-cm plate and transfected with the aid of the JetPEI reagent (PolyPlus Transfection) according to the manufacturer's instructions. Transfection efficiencies were typically above 70%. GSNO treatment was performed 18 h after transfection.

RNA Analysis-- Total RNA was extracted using the ULTRASPEC (Biotex Laboratories) reagent. Semi-quantitative reverse transcriptase (RT)-PCR was performed as described previously (29) using the following primer combinations: hp53, 5'-TGCAGCTGTGGGTTGATTC-3' and 5'-TCCGTCCCAGTAGATTACCA-3'; hp21, 5'-CGCGACTGTGATGCGCTAATG-3' and 5'-GGAACCTCTCATTCAACCGCC-3'; HDM2, 5'-GTGCAATACCAACATGTCTG-3' and 5'-GCATCAAGATCCGGATTCGA-3'; Mdm2, 5'-CGACTATTCCCAACCATCG-3' and 5'-CTAGTTGAAGTAACTTAGCACAAT-3'; and GAPDH, 5'-CAGCAATGCATCCTGCACC-3' and 5'-TGGACTGTGGTCATGAGCCC-3'.

Immunoblotting Analysis-- Cells were washed with ice-cold PBS and lysed in radioimmune precipitation buffer. After three rounds of vigorous vortexing at 5-min intervals, the lysates were cleared by centrifugation at 4 °C for 10 min. Aliquots containing 20 µg of total protein (Bio-Rad protein assay) were resolved on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes (BA83, Schleicher & Schuell). Membranes were probed with the antibodies indicated in the corresponding figure legends and developed with the ECL kit (Amersham Biosciences).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

NO Induces p53 Accumulation in a Variety of Cell Types-- To test the generality of the p53 response to NO, several different cell types were exposed to NO donors (either SNAP or GSNO), and p53 protein levels were monitored by Western blot analysis. A significant induction of endogenous p53 was seen in all wild type p53-containing cell types tested including the U2-OS human osteosarcoma cell line (Fig. 1A), the ML-1 human myeloid leukemia cell line (Fig. 1B), WI-38 human diploid fibroblasts (Fig. 1C), and MEFs (Fig. 3). The accumulation of p53 was time-dependent (Fig. 1A) and NO donor concentration-dependent (Fig. 1B) and was seen with both SNAP (Fig. 1, A and B) and GSNO (Fig. 1C). Importantly, the addition of a NO scavenger, C-PTIO (10 µM), completely abolished the GSNO-induced increase in p53 but not the induction of p53 by ionizing radiation (Fig. 1C, lower panel), confirming that the effect of GSNO on p53 is indeed mediated specifically by NO. Hence, in agreement with earlier reports (25-27, 30), the pathways linking NO signaling to p53 are functional in many cell types including cancer-derived cells that retain wild type p53 expression.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 1.   Time and dose-dependent induction of p53 by NO in different cell types. A, U2-OS human osteosarcoma cells were exposed to the NO donor SNAP at a final concentration of 0.5 mM. Cell extracts were prepared after different times of treatment as indicated in hours (T(h)) above each lane. Aliquots containing equal amounts of total protein were subjected to Western blot analysis with a mixture of the p53-specific antibodies DO-1 and PAb1801. B, ML-1 human myeloid leukemia cells were exposed to the indicated amounts of SNAP. Extracts were prepared after 10 h of treatment and processed as in A but using the p53-specific antibody PAb421. C, WI-38 human diploid fibroblasts were exposed to 8 Grays of ionizing radiation (IR) from a gamma -ray source or to the NO donor GSNO (1 mM final concentration). In the cultures analyzed in the bottom panel, the NO scavenger c-PTIO was added to the medium 1 h before treatment. Extracts were prepared and analyzed as in A. Ctr, nontreated control.

The accumulation of p53 in response to NO was accompanied by induction of the p53 target genes p21/Waf1 (Fig. 2A) and hdm2 (Fig. 2B) observed at both protein and mRNA levels. Hence, as reported previously (31), the p53 protein induced by NO is transcriptionally active.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   NO-induced p53 is transcriptionally active. C3 human lymphocytes were treated with 1 mM GSNO. A, protein extracts and total RNA were prepared at various time points after the addition of GSNO. B, both protein and RNA were extracted from parallel cultures after 4 h of treatment. Changes in protein and mRNA levels of the p53 target genes p21 (A) and hdm2 (B) were monitored by Western blot analysis and semi-quantitative RT-PCR, respectively. p53 protein was assessed as in Fig. 1. Ctr, nontreated control. IR, ionizing radiation gamma -irradiation (8 Grays). GAPDH mRNA was used as a control reference for total mRNA levels.

NO Increases p53 Protein Stability-- The increase in p53 protein in response to NO might be because of either increased levels of p53 mRNA or translational and post-translational events. However, no changes in the concentration of p53 mRNA could be found when p53-specific RT-PCR analysis was performed with the samples used in Fig. 2 (data not shown). Hence, we asked whether the accumulation of p53 was attributed to increased protein stability. To that end, a cycloheximide chase experiment was performed with MEFs maintained either in the presence or absence of the NO donor GSNO. As shown in Fig. 3, exposure to GSNO elicited a significant prolongation of the half-life of p53. An analysis by quantitative densitometry revealed that whereas the half-life of p53 in untreated MEFs was ~15 min, it increased to 140 min in GSNO-treated cells (data not shown). Thus, NO can indeed reduce the rate of p53 degradation and cause p53 protein stabilization; this is in line with the observations of Ho et al. (30) using cancer cell lines.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 3.   NO induces p53 protein stabilization. Primary MEFs were incubated for 6 h in the presence or absence of 1 mM GSNO. At that point, cycloheximide (CHX) was added to all cultures to a final concentration of 10 µg/ml. Extracts were prepared at the indicated time points thereafter and subjected to Western blot analysis with a mixture of the p53-specific monoclonal antibodies PAb421 and PAb248. Vinculin was used as a loading control.

Induction of p53 by NO Is Independent of ATM, PARP, and ARF-- NO can modify proteins by nitrosylation or nitration as well as cause DNA strand breaks (32, 33). The ATM kinase plays a pivotal role in the induction of p53 by agents such as ionizing radiation, which cause double strand DNA breaks (34, 35). Therefore, it is conceivable that NO may lead to p53 accumulation through induction of double strand breaks and consequent activation of ATM. This notion was addressed by comparing the ability of NO to cause p53 accumulation in cells with different ATM status. As shown in Fig. 4A, NO induced p53 to comparable levels in fibroblasts retaining a functional allele of the ATM gene (ATM +/-) and in their counterparts lacking completely ATM function (ATM-/-). As expected and unlike the case for NO, the induction of p53 by ionizing radiation was severely impaired in these ATM-null cells (data not shown). It is of note that basal p53 levels were moderately constitutively elevated in the ATM-null cells (Fig. 4A). Hence, ATM activity is dispensable for the activation of p53 by NO. This conclusion was also confirmed by monitoring the reactivity of Mdm2 with the monoclonal antibody 2A10. Phosphorylation of Mdm2 by ATM leads to a substantial drop in 2A10 reactivity (13, 36). However, exposure of cells to NO did not cause any measurable change in the reactivity of Mdm2 with 2A10 (data not shown), arguing that NO does not trigger ATM activation.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 4.   Induction of p53 by NO occurs independently of ATM, PARP-1, or ARF. A, human diploid fibroblasts heterozygous or homozygous for ATM gene mutations (ATM +/- and ATM-/-, respectively) were treated with the NO donor GSNO (1 mM) for 10 h. Steady-state levels of p53 were determined by Western blot analysis using a mixture of PAb1801 and DO-1. The same membrane was subsequently probed for vinculin as a loading control. B, PARP-1 knock-out mouse 3T3 fibroblasts were infected either with a recombinant retrovirus encoding PARP-1 (v-PARP-1,+) or with control pBabe-puro retrovirus (v-PARP-1, -) and incubated with or without 1 mM GSNO for 10 h. Cell extracts were subjected to Western blot analysis using a mixture of the p53-specific monoclonal antibodies PAb421 and PAb248, the Mdm2-specific monoclonal antibody 2A10, or a polyclonal antibody directed against PARP-1. alpha -Tubulin served as a loading control. C, embryonic fibroblasts derived either from control mice (MEFs) or from ARF-knock-out mice (ARF-/-) were treated with 1 mM GSNO for 10 h. p53, Mdm2, and alpha -tubulin were analyzed as in B. The upper band in the apparent p53 doublet is probably a nonspecific background band.

An attractive candidate for mediating the activation of p53 by NO is the enzyme PARP-1. NO is a potent activator of PARP-1 through its ability to cause single strand DNA breaks (37, 38). Furthermore, PARP-1 can engage in direct protein-protein interactions with p53 (39). Therefore, we compared the induction of p53 by NO in 3T3 fibroblasts from PARP-1 knock-out mice (40) and in derivatives of these 3T3 fibroblasts in which PARP-1 expression had been reconstituted by infection with a PARP-1 retrovirus. As shown in Fig. 4B, there was no measurable difference between these two cell types with regard to either p53 protein accumulation or induction of Mdm2, a product of a p53 target gene. Thus, PARP-1 appears dispensable for the activation of p53 by NO.

Some signaling pathways, in particular oncogenic stress, lead to p53 stabilization by triggering the synthesis of the ARF tumor suppressor protein (17). The binding of ARF to Mdm2 inactivates the latter and renders p53 more stable. Therefore, it was of interest to find out whether ARF played a role in the signaling from NO to p53. To that end, the effect of NO on p53 was studied in MEFs from ARF-null mice and in their wild type counterparts. As seen in Fig. 4C, the ablation of ARF expression did not compromise the ability of NO to promote an increase in the steady-state levels of p53 and Mdm2, implying that ARF is not required for the activation of p53 by NO.

NO Down-regulates Mdm2 Protein Levels-- Because the degradation of p53 is largely dependent on the activity of Mdm2, we performed a more detailed time course analysis of p53 and Mdm2 in wild type MEFs exposed to NO donors. Unexpectedly, although extended exposure to NO augmented the levels of Mdm2 owing to the activation of the mdm2 gene by p53 (see Fig. 4C), an opposite picture was revealed at early phases of the NO response. As seen in Fig. 5A, exposure of MEFs to GSNO led to a rapid drop in Mdm2 protein, clearly preceding the rise in p53. As expected, Mdm2 levels increased again and became further augmented at later time points, subsequent to the induction of p53 as also seen in Fig. 2B.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 5.   Down-regulation of Mdm2 by NO. A, wild type MEFs were treated with 1 mM GSNO for the indicated times. Cell extracts were prepared and subjected to Western blot analysis of p53, Mdm2, and alpha -tubulin as a loading control. Antibodies were as in Fig. 4B. The upper band in the apparent p53 doublet is probably a nonspecific background band. B, H1299 cells were treated with 1 mM GSNO for 4 or 10 h, and Hdm2 was detected with monoclonal antibody 2A9. beta -Catenin was used as a loading control. C, spontaneously immortalized fibroblasts derived from p53 knock-out mice (cell line 35-8) were treated with 1 mM GSNO for 1, 2, or 4 h. At each time point, protein extracts and total RNA were prepared from parallel cultures. Protein extracts were subjected to Western blot analysis using separately the Mdm2-specific monoclonal antibodies 2A10 and 4B2. RNA samples were subjected to semi-quantitative RT-PCR using primers specific for either Mdm2 or GAPDH as a control.

The ability of NO to modulate the levels of Mdm2 was further explored in p53-null cells where the analysis is made simpler by the absence of a later Mdm2 induction attributed to p53 activation. Indeed, incubation of p53-deficient H1299 human lung adenocarcinoma cells with GSNO resulted in a substantial and extended drop in Hdm2 (Fig. 5B). Consistent with the absence of p53, a second wave of Hdm2 induction did not occur in these cells. A pronounced decrease in Mdm2 quantified with the aid of two different monoclonal antibodies was also evident in GSNO-treated p53-null MEFs (Fig. 5C, left-hand panel). This decrease was not the result of down-modulation of mdm2 mRNA, because semi-quantitative RT-PCR analysis did not reveal any significant change in the concentration of the corresponding transcripts (Fig. 5C, right-hand panel). Together, these observations support the notion that the induction of p53 by NO, at least in the early phase of the response, is achieved through down-regulation of Mdm2 protein levels.

NO Attenuates p53 Ubiquitination by Endogenous Mdm2-- Mdm2 promotes p53 degradation by driving p53 ubiquitination. Therefore, it appeared plausible that the stabilization of p53 by NO is attributed to reduced p53 ubiquitination as a result of the drop in total Mdm2 levels. This observation was investigated in p53-deficient human colorectal carcinoma HCT116 cells (28). First, to confirm that the effect of NO could also be exerted on exogenous p53, these cells were transfected with a very small amount of p53 expression plasmid. As seen in Fig. 6A, NO indeed augmented the accumulation of the transfected p53 protein along with a reduction in the levels of endogenous Hdm2 protein. However, the total amounts of p53 produced in these transfected cultures were too low to allow further analysis of p53 ubiquitination. Therefore, a similar experiment was performed using higher inputs of p53 expression plasmid DNA. An analysis of relatively small aliquots of the resultant cell extracts revealed again the expected drop in Hdm2 (Fig. 6B, right-hand panel). However, this time there was no significant increase in p53, presumably because the transfected p53 was in large excess over endogenous Hdm2. These conditions simplified the quantitative analysis of p53 ubiquitination, because no adjustment had to be made for differences in total p53 protein. Importantly, when larger amounts of the same extracts were subjected to analysis with p53-specific antibodies, a significant reduction was observed in the intensity of the bands corresponding to ubiquitinated forms of p53 (Fig. 6B, left-hand panel). A similar picture was seen when HCT116 cells were cotransfected with expression plasmids for p53 and hemagglutinin-ubiquitin followed by analysis of p53-ubiquitin conjugates (data not shown). Hence, the NO-induced drop in total Mdm2 protein is accompanied by a corresponding drop in p53 ubiquitination, which presumably underlies the subsequent stabilization of p53.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 6.   NO attenuates p53 ubiquitination. A, HCT116 human colorectal carcinoma cells, rendered p53-null by somatic gene knock-out, (28) were transfected with 2 ng of p53 expression plasmid/6-cm dish, employing the JetPEI reagent. 18 h later, cells were treated with 1 mM GSNO for 2 h. Protein extracts were prepared and subjected to Western blot analysis of Hdm2 (monoclonal antibody 2A9) and p53 (mixture of monoclonal antibodies PAb1801 and DO-1). A green fluorescent protein expression plasmid was also included in all transfections as a control, and the corresponding protein was visualized with the aid of a green fluorescent protein-specific antibody (Roche Molecular Biochemicals). B, p53-null HCT116 cells were transfected with 50 ng of p53 expression plasmid/6-cm dish, employing the JetPEI reagent. 18 h later, cells were treated with 1 mM GSNO for 10 h, and cell extracts were subjected to Western blot analysis using the same antibodies as in A. The right-hand side panels of B depict the analysis of a small amount of extract; endogenous vinculin served as a loading control. In the left-hand side panel of B, larger amounts of the same extracts were loaded to enable better visualization of ubiquitinated forms of p53 (Ub-p53).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The mechanisms underlying the stress-induced stabilization and activation of p53 are being extensively studied (3, 4, 10, 41, 42). Although the ability of NO to up-regulate p53 is well documented, the detailed molecular analysis of the underlying mechanisms is complicated by the fact that NO is a very pleiotropic agent, which can cause several different types of protein modifications, lipid oxidation, and DNA strand breaks. NO causes DNA damage through its derivatives dinitrogen trioxide (N2O3 = NO + NO2-) and peroxynitrite (ONOO-). The resultant types of DNA damage include cross-linking, formation of abasic sites, and single strand breaks (reviewed in Ref. 32). The utilization of cells bearing deficiencies in several DNA damage-induced pathways enabled us to rule out some of those pathways as key mediators of the activation of p53 by NO. Thus, ATM was found to be dispensable for such activation, arguing against a major role of double-stranded DNA breaks. A more probable candidate was PARP-1, because this enzyme can be strongly activated by NO and because it has been implicated by several studies in the DNA damage-induced p53 response (43-46). Furthermore, PARP-1 coimmunoprecipitates with p53 and can bind noncovalently to three different regions of p53 (residues 153-178, 231-253, and 326-348), one of which is adjacent to the p53 nuclear export signal (39, 47, 48). The binding of PARP-1 to the p53 region adjacent to its nuclear export signal raises the interesting possibility that PARP-1 might increase the nuclear retention of p53 and thereby stabilize it. However, our findings do not support a role for PARP-1 in NO signaling to p53. Nevertheless, we can not rule out the possibility that the recently described PARP-2 protein (49) as well as other DNA damage-induced signaling events may play a role in p53 activation by NO. Similarly, our findings also appear to exclude ARF as a major contributor to NO-induced p53 accumulation. This sets NO clearly apart from oncogenic stress, which utilizes ARF to neutralize Mdm2-mediated p53 ubiquitination and degradation (17).

Rather, our data suggest that a biphasic mechanism is responsible for the up-regulation of p53 by NO. In the first phase, typically occurring within a few hours after exposure, NO leads to a pronounced decrease in Mdm2 protein levels. This is followed by a drop in p53 ubiquitination, leading to an initial rise in p53 protein. It is conceivable that the lower levels of Mdm2 also enable p53 to escape more efficiently the inhibitory effects because of the masking of its transactivation domain by the bound Mdm2. As a consequence, the accumulated p53 is likely to be more active as a transcription factor. In the second phase, Mdm2 levels rise again as a result of the transactivation of the mdm2 gene by the activated p53. This phase presumably occurs only if the high levels of NO persist beyond the first few hours. At present, our findings do not explain the ability of p53 to persist at elevated levels despite this surge in Mdm2 expression. However, as is the case in other stress conditions, it is conceivable that this persistence is at least in part the result of multiple covalent modifications on both p53 and Mdm2 (3, 4, 10, 41, 42). Of note, it has been reported that NO elicits a specific pattern of p53 phosphorylation events that is distinct from that known to occur in response to other stress signals (31). Such phosphorylation might underlie, at least to some extent, the resistance of p53 to Mdm2 after long exposure to NO.

Down-regulation of Mdm2 has been observed in a number of other situations that give rise to p53 activation including UV radiation and several DNA-damaging cancer therapy agents, as well as hypoxia (10, 50-52). With UV and other DNA-damaging agents, the ablation of Mdm2 was found to be largely the result of down-regulation of mdm2 gene expression. As shown here, this is not the case for NO, because no change in the abundance of mdm2 transcripts could be observed at a time when Mdm2 protein levels were markedly reduced. In contrast, the mechanism underlying the down-modulation of Mdm2 by hypoxia (52) could be more similar to that employed by NO, particularly because hypoxia can up-regulate cellular NO levels through induction of iNOS expression (53, 54). In that regard, it is of note that p53 has been shown to be a negative regulator of iNOS expression (26). Thus, iNOS appears to be part of a negative autoregulatory feedback loop, which on one hand the NO generated by iNOS drives p53 activation, whereas on the other hand this activated p53 down-regulates iNOS expression and thereby restrains further NO production (26).

In conclusion, our findings further underscore the multiplicity of molecular mechanisms employed by different stress signals to activate p53 as well as the central role of Mdm2 in these signaling pathways.

    ACKNOWLEDGEMENTS

We thank Drs. J. F. Martinez Leal and H. Matsumoto for helpful advice, Dr. C. Sherr for ARF knock-out cells, Dr. B. Vogelstein for p53-deleted HCT116 cells, and Dr. G. Lozano for 35-8 cells.

    FOOTNOTES

* This work was supported in part by NCI, National Institutes of Health Grant RO1 CA 40099, The U. S. A.-Israel Binational Science Foundation, the Kadoorie Charitable Foundations, the Center for Excellence Program of the Israel Science Foundation, and the Yad Abraham Center for Cancer Diagnosis and Therapy.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Tel.: 972-8-9342358; Fax: 972-8-9465223; E-mail: moshe.oren@weizmann.ac.il.

Published, JBC Papers in Press, February 26, 2002, DOI 10.1074/jbc.M112068200

    ABBREVIATIONS

The abbreviations used are: E3, ubiquitin-protein isopeptide ligase; ATM, ataxia telangiectasia-mutated; ARF, Alternative Reading Frame product of the INK4A tumor suppressor locus; NO, nitric oxide; iNOS, inducible nitric-oxide synthase; MEF, mouse embryonic fibroblasts; FBS, fetal bovine serum; PARP-1, poly(ADP-ribose) polymerase 1; SNAP, s-nitroso-n-acetylpenicillamine; GSNO, S-nitroso-glutathione; PBS, phosphate-buffered saline; C-PTIO, 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide; RT, reverse transcriptase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Vogelstein, B., Lane, D., and Levine, A. J. (2000) Nature 408, 307-310[CrossRef][Medline] [Order article via Infotrieve]
2. Evan, G. I., and Vousden, K. H. (2001) Nature 411, 342-348[CrossRef][Medline] [Order article via Infotrieve]
3. Oren, M. (1999) J. Biol. Chem. 274, 36031-36034[Free Full Text]
4. Woods, D. B., and Vousden, K. H. (2001) Exp. Cell Res. 264, 56-66[CrossRef][Medline] [Order article via Infotrieve]
5. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997) Nature 387, 296-299[CrossRef][Medline] [Order article via Infotrieve]
6. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. (1997) Nature 387, 299-303[CrossRef][Medline] [Order article via Infotrieve]
7. Honda, R., Tanaka, H., and Yasuda, H. (1997) FEBS Lett. 420, 25-27[CrossRef][Medline] [Order article via Infotrieve]
8. Wu, X. W., Bayle, J. H., Olson, D., and Levine, A. J. (1993) Genes Dev. 7, 1126-1132[Abstract/Free Full Text]
9. Barak, Y., Juven, T., Haffner, R., and Oren, M. (1993) EMBO J. 12, 461-468[Medline] [Order article via Infotrieve]
10. Ashcroft, M., Taya, Y., and Vousden, K. H. (2000) Mol. Cell. Biol. 20, 3224-3233[Abstract/Free Full Text]
11. Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., and Ziv, Y. (1998) Science 281, 1674-1677[Abstract/Free Full Text]
12. Canman, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., and Siliciano, J. D. (1998) Science 281, 1677-1679[Abstract/Free Full Text]
13. Maya, R., Balass, M., Kim, S. T., Shkedy, D., Leal, J. F., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., Kastan, M. B., Katzir, E., and Oren, M. (2001) Genes Dev. 15, 1067-1077[Abstract/Free Full Text]
14. Chehab, N. H., Malikzay, A., Appel, M., and Halazonetis, T. D. (2000) Genes Dev. 14, 278-288[Abstract/Free Full Text]
15. Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y., and Prives, C. (2000) Genes Dev. 14, 289-300[Abstract/Free Full Text]
16. Honda, R., and Yasuda, H. (1999) EMBO J. 18, 22-27[CrossRef][Medline] [Order article via Infotrieve]
17. Sherr, C. J., and Weber, J. D. (2000) Curr. Opin. Genet. Dev. 10, 94-99[CrossRef][Medline] [Order article via Infotrieve]
18. Lowe, S. W. (1999) Endocr. Relat. Cancer 6, 45-48[Abstract]
19. Damalas, A., Kahan, S., Shtutman, M., Ben-Ze'ev, A., and Oren, M. (2001) EMBO J. 20, 4912-4922[CrossRef][Medline] [Order article via Infotrieve]
20. Tao, W., and Levine, A. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 6937-6941[Abstract/Free Full Text]
21. Weber, J. D., Kuo, M. L., Bothner, B., DiGiammarino, E. L., Kriwacki, R. W., Roussel, M. F., and Sherr, C. J. (2000) Mol. Cell. Biol. 20, 2517-2528[Abstract/Free Full Text]
22. Schmidt, H. H., and Walter, U. (1994) Cell 78, 919-925[CrossRef][Medline] [Order article via Infotrieve]
23. Zweier, J. L., Samouilov, A., and Kuppusamy, P. (1999) Biochim. Biophys. Acta 1411, 250-262[Medline] [Order article via Infotrieve]
24. Gaston, B. (1999) Biochim. Biophys. Acta 1411, 323-333[Medline] [Order article via Infotrieve]
25. Messmer, U. K., Ankarcrona, M., Nicotera, P., and Brune, B. (1994) FEBS Lett. 355, 23-26[CrossRef][Medline] [Order article via Infotrieve]
26. Forrester, K., Ambs, S., Lupold, S. E., Kapust, R. B., Spillare, E. A., Weinberg, W. C., Felley-Bosco, E., Wang, X. W., Geller, D. A., Tzeng, E., Billiar, T. R., and Harris, C. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2442-2447[Abstract/Free Full Text]
27. Matsumoto, H., Hayashi, S., Hatashita, M., Shioura, H., Ohtsubo, T., Kitai, R., Ohnishi, T., and Kano, E. (1999) Nitric Oxide 3, 180-189[CrossRef][Medline] [Order article via Infotrieve]
28. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., and Vogelstein, B. (1998) Science 282, 1497-1501[Abstract/Free Full Text]
29. Israeli, D., Tessler, E., Haupt, Y., Elkeles, A., Wilder, S., Amson, R., Telerman, A., and Oren, M. (1997) EMBO J. 16, 4384-4392[CrossRef][Medline] [Order article via Infotrieve]
30. Ho, Y. S., Wang, Y. J., and Lin, J. K. (1996) Mol. Carcinogen. 16, 20-31[CrossRef][Medline] [Order article via Infotrieve]
31. Nakaya, N., Lowe, S. W., Taya, Y., Chenchik, A., and Enikolopov, G. (2000) Oncogene 19, 6369-6375[CrossRef][Medline] [Order article via Infotrieve]
32. Burney, S., Caulfield, J. L., Niles, J. C., Wishnok, J. S., and Tannenbaum, S. R. (1999) Mutat. Res. 424, 37-49[Medline] [Order article via Infotrieve]
33. Hess, D. T., Matsumoto, A., Nudelman, R., and Stamler, J. S. (2001) Nat. Cell Biol. 3, E46-E49[CrossRef][Medline] [Order article via Infotrieve]
34. Kastan, M. B., and Lim, D. S. (2000) Nat. Rev. Mol. Cell Biol. 1, 179-186[CrossRef][Medline] [Order article via Infotrieve]
35. Shiloh, Y. (2001) Curr. Opin. Genet. Dev. 11, 71-77[CrossRef][Medline] [Order article via Infotrieve]
36. Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shilo, Y., and Shkedy, D. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 14973-14977[Abstract/Free Full Text]
37. Radons, J., Heller, B., Burkle, A., Hartmann, B., Rodriguez, M. L., Kroncke, K. D., Burkart, V., and Kolb, H. (1994) Biochem. Biophys. Res. Commun. 199, 1270-1277[CrossRef][Medline] [Order article via Infotrieve]
38. Pieper, A. A., Verma, A., Zhang, J., and Snyder, S. H. (1999) Trends Pharmacol. Sci. 20, 171-181[CrossRef][Medline] [Order article via Infotrieve]
39. Malanga, M., Pleschke, J. M., Kleczkowska, H. E., and Althaus, F. R. (1998) J. Biol. Chem. 273, 11839-11843[Abstract/Free Full Text]
40. Oliver, F. J., Menissier-de Murcia, J., Nacci, C., Decker, P., Andriantsitohaina, R., Muller, S., de la Rubia, G., Stoclet, J. C., and de Murcia, G. (1999) EMBO J. 18, 4446-4454[CrossRef][Medline] [Order article via Infotrieve]
41. Prives, C., and Hall, P. A. (1999) J. Pathol. 187, 112-126[CrossRef][Medline] [Order article via Infotrieve]
42. Hupp, T. R. (1999) Cell Mol. Life Sci. 55, 88-95[CrossRef][Medline] [Order article via Infotrieve]
43. Whitacre, C. M., Hashimoto, H., Tsai, M. L., Chatterjee, S., Berger, S. J., and Berger, N. A. (1995) Cancer Res. 55, 3697-3701[Abstract/Free Full Text]
44. Wang, X., Ohnishi, K., Takahashi, A., and Ohnishi, T. (1998) Oncogene 17, 2819-2825[CrossRef][Medline] [Order article via Infotrieve]
45. Wesierska-Gadek, J., Wang, Z. Q., and Schmid, G. (1999) Cancer Res. 59, 28-34[Abstract/Free Full Text]
46. Wesierska-Gadek, J., and Schmid, G. (2001) Cell Mol. Biol. Lett. 6, 117-140[Medline] [Order article via Infotrieve]
47. Pleschke, J. M., Kleczkowska, H. E., Strohm, M., and Althaus, F. R. (2000) J. Biol. Chem. 275, 40974-40980[Abstract/Free Full Text]
48. Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., and Wahl, G. M. (1999) EMBO J. 18, 1660-1672[CrossRef][Medline] [Order article via Infotrieve]
49. Ame, J. C., Rolli, V., Schreiber, V., Niedergang, C., Apiou, F., Decker, P., Muller, S., Hoger, T., Menissier-de Murcia, J., and de Murcia, G. (1999) J. Biol. Chem. 274, 17860-17868[Abstract/Free Full Text]
50. Wu, L., and Levine, A. J. (1997) Mol. Med. 3, 441-451[Medline] [Order article via Infotrieve]
51. Ma, Y., Yuan, R., Meng, Q., Goldberg, I. D., Rosen, E. M., and Fan, S. (2000) Mol. Cell Biol. Res. Commun. 3, 122-128[CrossRef][Medline] [Order article via Infotrieve]
52. Alarcon, R., Koumenis, C., Geyer, R. K., Maki, C. G., and Giaccia, A. J. (1999) Cancer Res. 59, 6046-6051[Abstract/Free Full Text]
53. Melillo, G., Musso, T., Sica, A., Taylor, L. S., Cox, G. W., and Varesio, L. (1995) J. Exp. Med. 182, 1683-1693[Abstract/Free Full Text]
54. Melillo, G., Taylor, L. S., Brooks, A., Musso, T., Cox, G. W., and Varesio, L. (1997) J. Biol. Chem. 272, 12236-12243[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J.-H. Lee, M.-W. Jeong, W. Kim, Y. H. Choi, and K.-T. Kim
Cooperative Roles of c-Abl and Cdk5 in Regulation of p53 in Response to Oxidative Stress
J. Biol. Chem., July 11, 2008; 283(28): 19826 - 19835.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Matsumoto, A. Takahashi, and T. Ohnishi
Nitric Oxide Radicals Choreograph a Radioadaptive Response
Cancer Res., September 15, 2007; 67(18): 8574 - 8579.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
R. Zhang, A. Ma, S. J. Urbanski, and D.-M. McCafferty
Induction of inducible nitric oxide synthase: a protective mechanism in colitis-induced adenocarcinoma
Carcinogenesis, May 1, 2007; 28(5): 1122 - 1130.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Azad, V. Vallyathan, L. Wang, V. Tantishaiyakul, C. Stehlik, S. S. Leonard, and Y. Rojanasakul
S-Nitrosylation of Bcl-2 Inhibits Its Ubiquitin-Proteasomal Degradation: A NOVEL ANTIAPOPTOTIC MECHANISM THAT SUPPRESSES APOPTOSIS
J. Biol. Chem., November 10, 2006; 281(45): 34124 - 34134.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Zeini, P. G. Traves, R. Lopez-Fontal, C. Pantoja, A. Matheu, M. Serrano, L. Bosca, and S. Hortelano
Specific Contribution of p19ARF to Nitric Oxide-Dependent Apoptosis.
J. Immunol., September 1, 2006; 177(5): 3327 - 3336.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-J. Lee, D.-C. Kim, B.-H. Choi, H. Ha, and K.-T. Kim
Regulation of p53 by Activated Protein Kinase C-{delta} during Nitric Oxide-induced Dopaminergic Cell Death
J. Biol. Chem., January 27, 2006; 281(4): 2215 - 2224.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A.-L. Li, H.-Y. Li, B.-F. Jin, Q.-N. Ye, T. Zhou, X.-D. Yu, X. Pan, J.-H. Man, K. He, M. Yu, et al.
A Novel eIF5A Complex Functions As a Regulator of p53 and p53-dependent Apoptosis
J. Biol. Chem., November 19, 2004; 279(47): 49251 - 49258.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
A. G. Granja, M. L. Nogal, C. Hurtado, J. Salas, M. L. Salas, A. L. Carrascosa, and Y. Revilla
Modulation of p53 Cellular Function and Cell Death by African Swine Fever Virus
J. Virol., July 1, 2004; 78(13): 7165 - 7174.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C.-Q. Li, A. I. Robles, C. L. Hanigan, L. J. Hofseth, L. J. Trudel, C. C. Harris, and G. N. Wogan
Apoptotic Signaling Pathways Induced by Nitric Oxide in Human Lymphoblastoid Cells Expressing Wild-Type or Mutant p53
Cancer Res., May 1, 2004; 64(9): 3022 - 3029.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. J. Hofseth, S.'i. Saito, S. P. Hussain, M. G. Espey, K. M. Miranda, Y. Araki, C. Jhappan, Y. Higashimoto, P. He, S. P. Linke, et al.
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation
PNAS, January 7, 2003; 100(1): 143 - 148.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.